XML 46 R25.htm IDEA: XBRL DOCUMENT v3.24.3
SUBSEQUENT EVENTS
9 Months Ended
Sep. 30, 2024
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS SUBSEQUENT EVENTS
In October 2024, the Company acquired all the remaining outstanding shares of Innovalve Bio Medical Limited ("Innovalve") for an aggregate cash purchase price of $300.0 million, subject to certain adjustments, plus an additional $25.0 million upon achievement of a certain regulatory milestone. Innovalve is a developer of a transcatheter mitral valve replacement system.
Prior to the acquisition date, the Company had previously paid $30.0 million for an option to acquire Innovalve, which the Company exercised in July 2024, and had an existing preferred stock investment in Innovalve of $3.5 million, which represented approximately a 4% interest in Innovalve (collectively, the "previously held interest"). The acquisition of the remaining equity interest in Innovalve is expected to be accounted for as a step acquisition in accordance with Accounting Standards Codification Topic 805, "Business Combinations."